Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23453244 | 0.81 | PIK3C3 (0.37) | L3MBTL1 | |
| SCHEMBL5375326 | 0.79 | LMNA (0.49) | ADRB2ADRB1ADRB3MAPK1ALDH1A1 | |
| SCHEMBL14839397 | 0.77 | ESR1 (0.42) | MAPK1ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL28845789 | 0.75 | PIK3C3 (0.33) | MAPK1ALDH1A1KDM4ELMNANPC1 | |
| SCHEMBL2325118 | 0.73 | TSHR (0.74) | ADRB2ADRB1ADRB3L3MBTL1TP53 | |
| SCHEMBL18867935 | 0.73 | TSHR (0.74) | ADRB2ADRB1ADRB3L3MBTL1TP53 | |
| SCHEMBL29604433 | 0.73 | TSHR (0.74) | ADRB2ADRB1ADRB3L3MBTL1TP53 | |
| SCHEMBL6764109 | 0.72 | HTT (0.48) | L3MBTL1HTTALDH1A1KDM4ELMNA | |
| SCHEMBL9108416 | 0.72 | TSHR (0.41) | MAPK1L3MBTL1TP53ALDH1A1LMNA | |
| SCHEMBL11422522 | 0.72 | TSHR (0.52) | MAPK1L3MBTL1TP53ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | UNIVERSITY OF DELAWARE (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | UNIVERSITY OF DELAWARE (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | UNIVERSITY OF DELAWARE (US) | 2023-09-26 | — | — | US | disclosed |
| US-20210164005-A1 | METHODS FOR INDUCING BIOORTHOGONAL REACTIVITY | UNIVERSITY OF DELAWARE (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210164005-A1 | METHODS FOR INDUCING BIOORTHOGONAL REACTIVITY | UNIVERSITY OF DELAWARE (US) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | TST, CYP4F8, CYP4Z1 | ADRB2 4010/4885ADRB1 4270/4885ADRB3 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.